Announced Mon, 25 May · 21:12 IST

The Board has approved allotment of 7,240 (Seven Thousand Two Hundred Forty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the eligible employees of the Company, upon exercise ....

Capital Market Events View source PDF

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-9.9%1-day move
₹1311.00
prior close
₹1358.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.5-3.8-2.3-4.7-9.9-8.5-13.7-11.9-14.5-14.6-15.3-8.5-2.6
Up moveDown movePending
AI summary

Entero Healthcare Solutions' Board approved audited FY2026 results showing consolidated revenue of Rs 65,912 million (up 29% YoY) and profit of Rs 1,458 million (up 36% YoY), driven by multiple acquisitions completed during the year. The company allotted 7,240 equity shares to employees exercising stock options under ESOP 2023, and granted fresh 7,300 options. Three independent directors were reappointed for a second term. The Board also approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through subsidiary Sai Pharma Distributors. The 8th AGM is scheduled for August 19, 2026.

Likely market impact

Strong financial performance with 36% profit growth validates the company's acquisition-led growth strategy. ESOP activities indicate management retention efforts. New acquisitions may boost future revenues but require integration execution.